Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual Meeting Preliminary data from the ongoing Phase ...
Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―― Live and ...
Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated ...
LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed ...
Title: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study ...
A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged ...
Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with ...
Please provide your email address to receive an email when new articles are posted on . Higher percentages of the U.S. population live closer to clinical trial sites than they did a decade ago.
SAN DIEGO, Dec. 13, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback